Strong margins, patient capital—2029 launches are the bet

Delivered 946 Cr (114.4% YoY consolidated); PAT 79.3 Cr (351.3% YoY). Mgmt claims 19.5–20% reflect organic growth; merger integration inflates total.

EBITDA 205 Cr on 946 rev = 21.7% margin (rounding). Q1 FY26 estimate ~16.1% base. Expansion is real.

Net debt 86 Cr, EBITDA 205 Cr = 0.42x leverage in Q1. Call says 0.1x is target; may be post-quarter number. Deleveraging is real, claim is optimistic.

Confirmed for US (high-potent strategy + vertical integration working). Domestic India growth claimed strong but not separately quantified; consistent with strong q1.

API flatness due to June war uncertainty (customers postponed); order recovery post-July confirmed. Forward claim is non-quantified optimism.

Q1 21.6% vs. Q1 FY26 ~16%. Vertical integration (US APIs from India) + operational leverage post-merger drove expansion; sustained sequentially vs. Q4.

BioForLife SPA signed (Italy launchpad). 150–200M aspiration added to prior call. Clear strategic focus narrowed vs. prior portfolio breadth.

Prior: 15% growth. Now: 13–15% FY27 API growth, overall similar. But long-term reaffirmed at 18% CAGR (implicit 3% upgrade on CAGR math).

First high-potent revenue from 2029+; main windfall post-2030. 5–7 yr gestation on all new molecules. Prior call lacked this specificity.

Phasing between quarters. Full-year EU growth expected 18–20% on INR basis (volume + pricing). Q1 typically lighter; Q3 stronger. No structural issue; new market ramp (Spain strong, Benelux/Germany behind).

Volume-led: 25% volume growth (Turkey, Brazil, Mexico). New product launches. Pricing & FX secondary.

Yes, margins sustainable. Restructuring moved volume products to India for cost advantage; vertical integration with API; maintains 50–55% market share. Small base, but durability confirmed.

Animal API ~100 Cr run rate (+20%+), Human API larger but growing slower. Flat Q1 due to June war pause; customers delaying procurement. July recovery started; Q2 expected best quarter in history.

No, API 13–15% double-digit FY27 overall. Animal Health API +20%+, but Human API is bigger base. Overall consolidated 13–15%. Not expecting 60% repeat.

R&D facility hired staff, ordered equipment. Manufacturing design finalized, construction starts next few weeks, target completion Jan–Feb for exhibit batch. On track.

Started 2 yrs ago on API (3 modules). Recently completed formulation R&D lab. Partnered with strategic oncology manufacturers. 5–6 products filed; first revenue expected 2029. Majority revenue post-2030. Long-cycle business.

Three pillars: (1) Compliance non-negotiable (regulatory, quality, EHS); (2) Governance strict; (3) Financial discipline. Combined entity overlap limited to API; Animal & Human formulations run parallel. Strategic M&A only (fit strategy, not just add numbers).

Minority 16–17% of total profit expected (US & Spain geographies). Will acquire 100% minority stake in 1–2 years. Evaluating BioForLife & other M&A timing.

Brand TAM 20B+, but API is 20% of formulation, price erodes 50–60% post-generic. Target 10–15% market share average (25–30% best case). Focus on Day 1 launch for sustainability vs. alternate supplier.

Learned from Alivira. Won't Indianize European ops; understand local market dynamics. Use as launchpad for Europe expansion, not cost arbitrage. Italian management, structure preserved. No manufacturing relocation.

Overall FY27 expected mid-teens growth (13–15% implied). Animal Health Formulation driving; Europe 18–20% on INR basis if volume+pricing held. US continued high-single-digit to low-double-digit.

18% CAGR = 1B by FY32 (6 years). Assumes sustained double-digit FY27–29, then 25%+ growth FY29–32 as first-to-file & BioForLife launches ramp. Companion animals 150–200M by 2032.

Q1 delivered 21.6%. Management indicated confidence in maintaining this level while investing in R&D & capex. US 34–35% EBITDA margins expected to sustain post-vertical integration.

Companion animal tablet capacity, high-potent formulation facility, API expansion (Albendazole, etc.), R&D investments. Evenly split between organic & potential M&A.

High-potent oncology & first-to-file portfolio require 5–7 year cycles. First revenue 2029. Main FY32 upside (25%+ growth) contingent on 2029–30 launches staying on track.

Post-merger integration with Viyash completed Q1. BioForLife Italy acquisition in pipeline. Prior Alivira (SeQuent) acquisition had structural issues & high costs. Management learning curve evident but risk remains on execution.

API business flat Q1 due to war-related customer wait-and-watch on raw material prices. Recovery expected Q2 but timing dependent. General API commodity pricing risk.

Europe revenue flat YoY in EUR constant currency (13% INR growth due to FX). Core markets (Spain) strong but new markets (Germany, Benelux) behind. BioForLife will take 18–24 months for registration & launch contribution.

Minority interest in US & Spain is 16–17% of profit (Rs. 13–14 Cr quarterly impact). Management plans to acquire 100% stake in 1–2 years but cost & timing uncertain.